Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics
about
Network-based approaches in drug discovery and early developmentLessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsLogic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab.Antibody therapy of pediatric B-cell lymphomaDeveloping Exposure/Response Models for Anticancer Drug Treatment: Special ConsiderationsModel-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein BiomarkersBiomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis.FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemiaSystems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity.Array of translational systems pharmacodynamic models of anti-cancer drugs.Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells.Using network biology to bridge pharmacokinetics and pharmacodynamics in oncology.Current mathematical models for cancer drug discovery.Feedback control indirect response models.
P2860
Q26827940-99C03284-6CBE-4F53-8118-4AA373658195Q26849243-61E07B28-93D7-46F1-8E7B-63920EEFB1DCQ35962054-5D43A52D-07A5-44A4-8EA4-2C996EBF8B65Q36094941-F23D1B2B-8C88-43FD-A483-4A1A6C8E8501Q36366424-6E85CA0F-AE0E-4B1C-B7B1-CB2FBC301E28Q36732959-E46A2B68-6EF6-4286-AD50-BD2D5B83CF31Q38557331-C4968419-8F31-4CDA-8AC7-56C62A43342BQ38847931-ABDA6495-7425-441D-B8E0-8A61354BF5B7Q38849422-2D491BD3-42BD-498D-B1B6-9184D56BB37DQ38946796-3CDAC04A-DEAF-4B11-82FB-DABDAC348731Q38962519-7D0A52D0-2C7F-42EE-BAFB-D5FA256A7739Q38988505-5B8AB249-BCAA-491B-A9E6-58086780BEA6Q39013265-94D25E0D-B2F8-4399-8AFB-77DD04B8BC9DQ39355451-FBC8F31B-DF06-417E-B364-230A90F148C4Q39359967-D0ED8B6E-0EF3-46DC-8A45-DDAF4C117D1FQ46520626-4C689D86-9720-45BC-B15D-E180ED38F955
P2860
Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Combinatorial chemotherapeutic ...... model of CD20 pharmacodynamics
@ast
Combinatorial chemotherapeutic ...... model of CD20 pharmacodynamics
@en
type
label
Combinatorial chemotherapeutic ...... model of CD20 pharmacodynamics
@ast
Combinatorial chemotherapeutic ...... model of CD20 pharmacodynamics
@en
prefLabel
Combinatorial chemotherapeutic ...... model of CD20 pharmacodynamics
@ast
Combinatorial chemotherapeutic ...... model of CD20 pharmacodynamics
@en
P2093
P2860
P1433
P1476
Combinatorial chemotherapeutic ...... model of CD20 pharmacodynamics
@en
P2093
Donald E Mager
John M Harrold
Robert M Straubinger
P2860
P304
P356
10.1158/0008-5472.CAN-11-2432
P407
P577
2012-02-20T00:00:00Z